Trial Profile

A phase 1 study of VMT01 for treating melanoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VMT 01 (Primary)
Indications Multiple myeloma
Focus Diagnostic use; First in man

Most Recent Events

03 Feb 2022 New trial record
19 Apr 2021 Status changed from planning to recruiting, according to a Viewpoint Molecular Targeting media release.
19 Jan 2021 According to a Viewpoint Molecular Targeting media release, company awarded 5 million dollar in phase II SBIR grants from the National Institutes of Health - National Cancer Institute Jan 19, 2021. Second year of a 2 million dollar phase II SBIR funding to begin this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com